Citadel Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-600
Closed -$26K – 14286
2021
Q4
$26K Sell
600
-640
-52% -$36.8K ﹤0.01% 13521
2021
Q3
$88K Sell
1,240
-1,420
-53% -$131K ﹤0.01% 12994
2021
Q2
$305K Sell
2,660
-435
-14% -$42.5K ﹤0.01% 11221
2021
Q1
$321K Buy
3,095
+1,330
+75% +$126K ﹤0.01% 10697
2020
Q4
$84K Buy
+1,765
New +$64.8K ﹤0.01% 10320

Other funds holding IMDX

Citadel Advisors's IMDX Position: Q3 2026 in Review

Citadel Advisors opened a new position in Insight Molecular Diagnostics (IMDX) in Q3 2026: 33,511 shares worth $120K. The stake represents ﹤0.01% of the portfolio and ranks #12767 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in IMDX as recently as Q4 2025.

Citadel Advisors first reported a position in IMDX in Q1 2018 and has held it in 19 quarters since. The position peaked at $603K in Q1 2021. 44 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.

  • Citadel Advisors held 33,511 shares of Insight Molecular Diagnostics worth $120K as of Q3 2026.
  • Insight Molecular Diagnostics was a new Citadel Advisors position in Q3 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #12767 holding.
  • Citadel Advisors first reported a position in Insight Molecular Diagnostics in Q1 2018 and has held it in 19 quarters since.
  • Citadel Advisors's Insight Molecular Diagnostics position peaked at $603K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.